- Home
- CEPU vs MYGN Comparison
CEPU vs MYGN Comparison
Compare CEPU & MYGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CEPU
- MYGN
- Stock Information
- Founded
- CEPU 1989
- MYGN 1991
- Country
- CEPU Argentina
- MYGN United States
- Employees
- CEPU N/A
- MYGN N/A
- Industry
- CEPU Electric Utilities: Central
- MYGN Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- CEPU Utilities
- MYGN Health Care
- Exchange
- CEPU Nasdaq
- MYGN Nasdaq
- Market Cap
- CEPU 2.1B
- MYGN 2.0B
- IPO Year
- CEPU 2018
- MYGN 1995
- Fundamental
- Price
- CEPU $13.84
- MYGN $15.12
- Analyst Decision
- CEPU Hold
- MYGN Buy
- Analyst Count
- CEPU 1
- MYGN 12
- Target Price
- CEPU $12.00
- MYGN $26.64
- AVG Volume (30 Days)
- CEPU 399.6K
- MYGN 1.0M
- Earning Date
- CEPU 11-08-2024
- MYGN 11-07-2024
- Dividend Yield
- CEPU 6.34%
- MYGN N/A
- EPS Growth
- CEPU 219.02
- MYGN N/A
- EPS
- CEPU 0.13
- MYGN N/A
- Revenue
- CEPU $375,582,169.00
- MYGN $823,600,000.00
- Revenue This Year
- CEPU $101.46
- MYGN $13.85
- Revenue Next Year
- CEPU $61.85
- MYGN $7.73
- P/E Ratio
- CEPU $11.81
- MYGN N/A
- Revenue Growth
- CEPU N/A
- MYGN 12.15
- 52 Week Low
- CEPU $7.07
- MYGN $14.72
- 52 Week High
- CEPU $14.15
- MYGN $29.30
- Technical
- Relative Strength Index (RSI)
- CEPU 81.11
- MYGN 18.92
- Support Level
- CEPU $11.09
- MYGN $14.72
- Resistance Level
- CEPU $13.94
- MYGN $15.68
- Average True Range (ATR)
- CEPU 0.64
- MYGN 0.93
- MACD
- CEPU 0.16
- MYGN -0.03
- Stochastic Oscillator
- CEPU 89.70
- MYGN 8.20
About CEPU Central Puerto S.A. (each represents ten)
Central Puerto SA is a private-sector power generation company. It is mainly engaged in electric power generation and commercialization. The company is also involved in the natural gas distribution public sector service in the Cuyo and Centro regions in Argentina. The Group has four reporting segments which includes electric power generation from conventional sources, electric power generation from renewable sources, natural gas transport and distribution, and forest activity.. The company derives maximum revenue from Electric Power Generation from conventional sources segment.
About MYGN Myriad Genetics Inc.
Myriad Genetics is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel with the capability to identify the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm offers biomarker discovery and companion diagnostic services to pharma and biotech companies.